Know Cancer

or
forgot password


Phase 2
18 Years
N/A
Not Enrolling
Both
Multiple Myeloma

Thank you

Trial Information


Inclusion Criteria:



1. Patients  18 years of age with a definite diagnosis of multiple myeloma.

2. Patients have been on a steady dose of INTRON®A for at least 6 weeks and have
tolerated it (randomized study only), or patients who within six weeks of starting
INTRON®A become intolerant (tolerability sub-study only)

3. Informed consent obtained

Exclusion Criteria:

- a) Patients with refractory Multiple Myeloma. b) Treatment with any investigational drug
within 30 days of entry to this protocol.

c) Subjects who are pregnant, nursing, or of reproductive potential and who are not
practising an effective means of contraception.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label

Principal Investigator

Ray Powles, FRCP, FRCpath

Investigator Role:

Principal Investigator

Investigator Affiliation:

Royal Marsden NHS Foundation Trust

Authority:

United Kingdom: Research Ethics Committee

Study ID:

1871

NCT ID:

NCT00323505

Start Date:

March 2001

Completion Date:

December 2004

Related Keywords:

  • Multiple Myeloma
  • Multiple Myeloma
  • Neoplasms, Plasma Cell

Name

Location